Drug Trial Radar · NCT05657184
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jul 19, 2021
Primary completion
Jun 9, 2023
Study completion Jun 9, 2023
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Peking Union Medical College Hospital; Ruijin Hospital; The First Affiliated Hospital of Guangzhou Medical University; Regend Therapeutics XLotus (Jiangxi) Co, Ltd.
- First posted
- Dec 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
REGEND001Drug
Transplantation of REGEND001 for dose escalation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of the cell therapy-related adverse events (AEs)Time frame: Within 24 weeks after treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.